Michael Rosenzweig, MD, assistant professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, discusses the standard of care for the treatment of patients with amyloidosis.

Autologous stem cell transplant, the current standard of care, is generally well tolerated by patients who are eligible, says Rosenzweig. For those who are not eligible, Rosenzweig says that a bortezomib (Velcade)-based regimen is often used, which is also generally well tolerated.

The treatment landscape of immunoglobulin light chain (AL) amyloidosis is rapidly expanding with novel systemic therapies such as daratumumab (Darzalex). Daratumumab is very well tolerated, and it is making its way to the frontline setting, says Rosenzweig. Clinical trials are underway exploring daratumumab in combination with bortezomib-based regimens for AL amyloidosis.

Videos

Dr. Rosenzweig Discusses the Standard of Care in Amyloidosis

Michael Rosenzweig, MD, assistant professor in the department of Hematology and Hematopoietic Cell Transplantation at City of Hope, discusses emerging agents in the treatment of patients with amyloidosis.

The standard approach to the treatment of amyloidosis is to attack the underlying small plasma cell clone that is responsible for the light chains that are producing amyloid and then depositing it in organs and tissues. The progress that has been made in developing therapies for amyloidosis goes hand-in-hand with the progress that has been made in multiple myeloma, says Rosenzweig.

Daratumumab (Darzalex) is an exciting new drug for relapsed myeloma, which is moving up to the frontline. It has also been studied in amyloidosis and has been found to be very effective, Rosenzweig says. There is a novel anti-amyloid fibril therapy under investigation in clinical trials called NEOD001, and another that is in earlier stages called 111F4. Both have shown preliminary signals of efficacy in patients with amyloidosis.

Michael Rosenzweig, MD

Articles

Dr. Rosenzweig Discusses the Standard of Care in Amyloidosis

Dr. Rosenzweig Discusses Emerging Agents in Amyloidosis